Identification and quantitative analysis of bioactive components from Potentilla kleiniana Wight et Arn with anti HIV-1 proteases activity

Nat Prod Res. 2023 Nov-Dec;37(23):4028-4031. doi: 10.1080/14786419.2022.2162513. Epub 2022 Dec 30.

Abstract

Potentilla kleiniana Wight et Arn(PK, 'Wu Pi Feng' in Chinese) was recorded as Miao ethnic medicine for treatment of fever, cough, ulcer, and erysipelas for thousands years. This study aimed to evaluate the antiviral activity of four PK extracts and seven compounds by using HIV-1 protease (HIV-1 PR). In addition, Ultra-High Performance Liquid Chromatography and High Resolution Mass Spectrometry (UPLC-HRMS) was employed to identify the bioactive components. The toxicity assessment of the extracts was done before antiviral screening using a highly specific human aspartyl protease, renin protease by fluorimetric method. As a result, seven compounds and four extracts of PK inhibited HIV-1 PR with IC50 range from 0.009 to 0.36 mg/mL, and did not appreciably inhibit the general human protease renin. This study first demonstrated that four PK extracts, ellagic acid and ursolic acid potent inhibit HIV-1 protease, could be used as an efficacious drug candidate to treat SARS-CoV-2 infection.

Keywords: HIV-1 protease; Potentilla kleiniana; bioactive components.

MeSH terms

  • Antiviral Agents / pharmacology
  • Endopeptidases
  • HIV-1*
  • Humans
  • Peptide Hydrolases
  • Potentilla*
  • Renin

Substances

  • Renin
  • Peptide Hydrolases
  • Endopeptidases
  • Antiviral Agents